Peptides for Andropause: Supporting Male Hormonal Decline with Targeted Protocols

Andropause—sometimes called male menopause, though the term is medically imprecise—describes the constellation of symptoms associated with the gradual hormonal decline that many men experience from their 40s onward. Unlike female menopause, which involves a relatively abrupt hormonal transition, andropause is a slow, insidious process. Testosterone declines at approximately 1–2% per year starting in the early 30s. Growth hormone falls roughly 15% per decade. DHEA follows a similar trajectory. IGF-1 drops proportionally with GH.

The clinical consequences are real and measurable: declining muscle mass, increasing body fat (particularly visceral), reduced libido, erection quality changes, cognitive dulling, mood shifts toward irritability or low-grade depression, reduced motivation, worsening sleep quality, and diminished athletic capacity. Many men attribute these changes to stress, lifestyle, or "just getting older" without recognizing the hormonal substrate driving them.

Peptides do not replace comprehensive andropause evaluation—which should include testosterone levels, free testosterone, SHBG, LH, FSH, prolactin, and thyroid function. But they address specific components of the hormonal milieu that testosterone replacement therapy (TRT) alone does not target, and for some men, they may defer or reduce the need for TRT.

The Hormonal Architecture of Andropause

Understanding which hormones are actually declining helps clarify which peptides are relevant.

Testosterone: The most discussed component. Primary testosterone decline originates at the testicular level (reduced Leydig cell output), the pituitary level (reduced LH secretion), and the hypothalamic level (reduced GnRH pulsatility). SHBG typically increases with age, binding more testosterone and reducing the biologically active free fraction.

Growth hormone and IGF-1: GH decline accelerates the body composition changes associated with andropause—increased visceral fat, reduced lean mass, slowed recovery—and compounds the testosterone-related deficits in anabolic signaling. Many men who believe their symptoms are purely testosterone-related have significant GH deficiency contributing.

DHEA: An adrenal androgen precursor that declines steadily from peak levels in the 20s. DHEA is a precursor to both testosterone and estrogen and supports mood, immune function, and cognitive performance.

Kisspeptin: The hypothalamic regulator of GnRH pulsatility. As men age, kisspeptin neuron activity declines, directly reducing GnRH pulse frequency and downstream LH/FSH/testosterone output. This represents an upstream intervention point that is now attracting significant research interest.

CJC-1295 and Ipamorelin: The GH Axis Foundation

The combination of CJC-1295 and ipamorelin represents the most clinically supported peptide protocol for andropause. It addresses the GH component of age-related hormonal decline with a safety and physiological profile far superior to exogenous HGH.

Together, CJC-1295 and ipamorelin stimulate the two receptors responsible for GH release—the GHRH receptor and the ghrelin receptor respectively—producing synergistic GH pulses that exceed what either achieves alone. The GH released is pulsatile rather than constant, maintaining the physiological pattern that governs downstream metabolic effects optimally.

For men in andropause, the benefits of GH optimization include:

• Improved body composition: Visceral fat reduction is one of the most consistently reported effects of GH optimization in GH-deficient adults. The combination of GH-stimulated lipolysis and improved insulin signaling in muscle produces meaningful shifts in fat-to-muscle ratio.
• Enhanced recovery: Slower recovery from exercise is a near-universal complaint in andropause. GH is a central driver of muscle protein synthesis and tissue repair—restoring GH pulsatility directly improves this.
• Sleep architecture: GH secretion is largest during slow-wave sleep, and GH itself promotes slow-wave sleep in a positive feedback loop. Many men on secretagogue protocols report improved sleep depth and morning energy.
• Cognitive function: IGF-1 has neuroprotective and neuroplastic effects in the hippocampus. Several men report improved word recall, mental clarity, and motivation within 6–12 weeks on GH secretagogue protocols—likely mediated through restored IGF-1 signaling.

Standard protocols for men in andropause: 100–200 mcg CJC-1295 combined with 100–200 mcg ipamorelin before sleep, 5 days per week, in 8–12 week cycles. Target IGF-1 restoration to 200–280 ng/mL.

Kisspeptin: The Testosterone Axis from the Top Down

Kisspeptin is generating substantial research interest as a potential tool for testosterone axis support in aging men. As the upstream regulator of GnRH pulsatility, kisspeptin administration can amplify LH secretion and, if testicular Leydig cells retain adequate function, stimulate testosterone production through the natural axis rather than bypassing it.

This distinction matters enormously for men who want to optimize testosterone without suppressing their natural production—the primary drawback of TRT. Exogenous testosterone creates negative feedback on the hypothalamic-pituitary axis, reducing LH and FSH to near-zero and causing testicular atrophy over time. Kisspeptin takes the opposite approach: stimulating the top of the axis to enhance natural production.

Clinical research on kisspeptin in aging men is at an early stage, but studies in hypogonadal men show kisspeptin administration can produce significant LH and testosterone elevations. The practical challenge is that kisspeptin requires multiple injections due to its short half-life in its native form. Modified kisspeptin analogues with longer activity are in development.

For men who want to support testosterone axis function without TRT, kisspeptin represents the most mechanistically logical option—one that works with the natural hormone axis rather than replacing it. It should be used under endocrinological supervision given the complexity of its effects on the reproductive axis.

BPC-157: Structural Maintenance and Vitality

Men in andropause face a compound problem with connective tissue: declining testosterone (which has direct anabolic effects on tendons and bone) combined with declining GH creates accelerated structural degradation that physical training increasingly fails to compensate for.

BPC-157 addresses the local tissue environment through mechanisms independent of systemic hormones. Its effects on tendon healing, joint inflammation, and cartilage maintenance are relevant to the musculoskeletal complaints that commonly accompany andropause.

For men experiencing:

• Chronic joint pain: BPC-157 cycles of 6–8 weeks at 250–500 mcg/day can reduce inflammation and support remodeling in chronically inflamed joints, particularly shoulders, knees, and lower back.
• Tendon injuries: The reduced healing capacity of andropause makes tendon injuries more persistent. BPC-157's documented acceleration of tendon repair in animal models translates to a compelling rationale for targeted injection near injury sites.
• GI issues: NSAID use for joint pain is common in andropause and creates GI lining damage. BPC-157's gastroprotective mechanisms directly address this secondary complication.

Testosterone-Supporting Peptides vs. TRT: How They Relate

It is important to clarify what peptides can and cannot do in the context of testosterone management.

Peptides can: support the GH axis (CJC-1295/ipamorelin), stimulate the natural testosterone axis from the hypothalamic level (kisspeptin), support the tissue environment that testosterone acts on (BPC-157), and address sleep and recovery to secondarily support hormonal production.

Peptides cannot: replace testosterone when primary hypogonadism is present (when the testes themselves have lost the capacity to produce adequate testosterone despite sufficient LH signaling), or reverse established testosterone deficiency to the degree that TRT can.

For men with confirmed low testosterone and clinical hypogonadism, TRT remains the most evidence-based intervention. Peptides in this context serve as complementary support—helping preserve natural axis function if TRT is being considered, or optimizing the systemic environment if TRT is already in use.

Men on TRT who want to maintain some testicular function and fertility use gonadorelin or HCG (human chorionic gonadotropin—an LH analogue) to maintain LH-like signaling despite TRT-induced suppression. Kisspeptin may eventually occupy a role in this context as well.

Managing Insulin Sensitivity and Metabolic Health

One of the underappreciated aspects of andropause is its metabolic component. Both testosterone and GH deficiency impair insulin sensitivity. Visceral fat accumulation—driven by both deficits—releases inflammatory cytokines and further worsens insulin resistance in a self-reinforcing cycle.

GH secretagogue protocols should be accompanied by monitoring of fasting glucose and HbA1c in men with andropause, as GH's anti-insulin effects can exacerbate underlying metabolic dysfunction. Timing injections before sleep (when insulin is naturally lowest) and avoiding carbohydrates 1–2 hours before injection minimizes this concern.

For men with significant metabolic syndrome alongside andropause, addressing insulin resistance through diet and exercise—or considering GLP-1 based interventions—may be a priority before adding GH-stimulating peptides.

Frequently Asked Questions

Q: Can peptides raise testosterone levels without TRT? A: Kisspeptin can stimulate the natural testosterone axis and may raise testosterone in men with secondary hypogonadism (where the testes still function but pituitary signaling is inadequate). CJC-1295/ipamorelin addresses the GH axis, not testosterone directly. Neither is a substitute for TRT when testosterone deficiency is severe.

Q: What bloodwork should I get before starting andropause peptides? A: Total testosterone, free testosterone, SHBG, LH, FSH, prolactin, IGF-1, estradiol, complete metabolic panel, CBC, PSA, and thyroid panel. This establishes the full hormonal picture and catches any issues that would change the protocol.

Q: Will GH secretagogues cause hair loss? A: GH itself does not cause hair loss. However, increased IGF-1 can theoretically amplify androgenic effects in genetically predisposed men—meaning it could accelerate existing male-pattern baldness in men with DHT sensitivity. Monitor for this if you are already experiencing hair thinning.

Q: How quickly will I notice effects from CJC-1295/ipamorelin? A: Sleep quality improvements are often reported within the first few weeks. Body composition changes typically become noticeable at 8–12 weeks with consistent protocol adherence. IGF-1 should be checked at 8 weeks to confirm response.

Q: Can I combine peptides with TRT? A: Generally yes. CJC-1295/ipamorelin and TRT address different axes and have no known adverse interactions. BPC-157 is also compatible. Kisspeptin in combination with TRT is more complex—discuss the specific interaction with your prescribing physician.